Vildagliptin in clinical practice: a review of literature

Bibliography

• Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:7-85
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281(21):2005-12
   PubMed Web of Science ®Google Scholar
• Nauck MA. Unraveling the science of incretin biology. Am J Med 2009; 122(6, Suppl 1):S3-S10
   PubMed Web of Science ®Google Scholar
• MacDonald PE, El-Kholy W, Riedel MJ, The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. Diabetes 2002;51(Suppl 3):S434-42
   PubMedGoogle Scholar
• Ahren B, Holst JJ, Mari A. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. Diabetes Care 2003;26(10):2860-4
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359(9309):824-30
   PubMed Web of Science ®Google Scholar
• Mest HJ, Mentlein R. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005;48(4):616-20
   PubMed Web of Science ®Google Scholar
• Brandt I, Joossens J, Chen X, Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}-pyrrolidine-2-carbonitrile). Biochem Pharmacol 2005;70(1):134-43
   PubMed Web of Science ®Google Scholar
• Burkey BF, Li X, Bolognese L, Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005;315(2):688-95
   PubMed Web of Science ®Google Scholar
• Burkey BF, Russel M, Wang K, Vildagliptin displays slow tight-binding to dipeptidyl peptidase (DPP)-4, but not DPP-8 or DPP-9. Diabetolgia 2006;49(Suppl 1)477-8
   Google Scholar
• Lankas GR, Leiting B, Roy RS, Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54(10):2988-94
   PubMed Web of Science ®Google Scholar
• Burkey BF, Hoffmann PK, Hassiepen U, Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited. Diabetes Obes Metab 2008;10(11):1057-61
   PubMed Web of Science ®Google Scholar
• He YL, Sadler BM, Sabo R, The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet 2007;46(9):787-802
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Riviere GJ, Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007;23(5):1131-8
   PubMed Web of Science ®Google Scholar
• He YL, Serra D, Wang Y, Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clin Pharmacokinet 2007;46(7):577-88
   PubMed Web of Science ®Google Scholar
• Sunkara G, Sabo R, Wang Y, Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. J Clin Pharmacol 2007;47(9):1152-8
   PubMed Web of Science ®Google Scholar
• Villhauer EB, Brinkman JA, Naderi GB, 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46(13):2774-89
   PubMed Web of Science ®Google Scholar
• He H, Tran P, Yin H, Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans. Drug Metab Dispos 2009;37(3):536-44
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Campestrini J, The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol 2007;63(7):677-86
   PubMed Web of Science ®Google Scholar
• Pratley RE, Rosenstock J, Pi-Sunyer FX, Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30(12):3017-22
   PubMed Web of Science ®Google Scholar
• Hu P, Yin Q, Deckert F, Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol 2009;49(1):39-49
   PubMed Web of Science ®Google Scholar
• Galvus, INN-vildagliptin. H-771-en6. 2007. EMEA
   Google Scholar
• Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment. Clinical Trials gov 2009: Available from: http://clinicaltrials.gov/ct2/show/NCT00567047
   Google Scholar
• Ahren B, Landin-Olsson M, Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004;89(5):2078-84
   PubMed Web of Science ®Google Scholar
• Mari A, Sallas WM, He YL, Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90(8):4888-94
   PubMed Web of Science ®Google Scholar
• D'Alessio DA, Denney AM, Hermiller LM, Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009;94(1):81-8
   PubMed Web of Science ®Google Scholar
• Mari A, Scherbaum WA, Nilsson PM, Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab 2008;93(1):103-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Foley JE, Rendell M, Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008;31(1):30-5
   PubMed Web of Science ®Google Scholar
• El-Ouaghlidi A, Rehring E, Holst JJ, The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab 2007;92(11):4165-71
   PubMed Web of Science ®Google Scholar
• Pospisilik JA, Martin J, Doty T, Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52(3):741-50
   PubMed Web of Science ®Google Scholar
• Augstein P, Berg S, Heinke P, Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance. Diabetes Obes Metab 2008;10(10):850-61
   PubMed Web of Science ®Google Scholar
• D'Alessio DA, Denney AM, Hermiller LM, Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J Clin Endocrinol Metab 2009;94(1):81-8
   PubMed Web of Science ®Google Scholar
• Azuma K, Radikova Z, Mancino J, Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93(2):459-64
   PubMed Web of Science ®Google Scholar
• Balas B, Baig MR, Watson C, The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92(4):1249-55
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28(8):1936-40
   PubMed Web of Science ®Google Scholar
• He YL, Wang Y, Bullock JM, Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47(5):633-41
   PubMed Web of Science ®Google Scholar
• Utzschneider KM, Tong J, Montgomery B, The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31(1):108-13
   PubMed Web of Science ®Google Scholar
• Balas B, Baig MR, Watson C, The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007;92(4):1249-55
   PubMed Web of Science ®Google Scholar
• Ahren B, Schweizer A, Dejager S, Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94(4):1236-43
   PubMed Web of Science ®Google Scholar
• Foley JE, Ligueros-Saylan M, He YL, Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes. Horm Metab Res 2008;40(10):727-30
   PubMed Web of Science ®Google Scholar
• Ristic S, Byiers S, Foley J, Holmes D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 2005;7(6):692-8
   PubMed Web of Science ®Google Scholar
• Kikuchi M, Abe N, Kato M, Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2009;83(2):233-40
   PubMed Web of Science ®Google Scholar
• Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39(3):218-23
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76(1):132-8
   PubMed Web of Science ®Google Scholar
• Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38(6):423-8
   PubMed Web of Science ®Google Scholar
• Schweizer A, Dejager S, Bosi E. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab 2009;11:804-12
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28(8):1936-40
   PubMed Web of Science ®Google Scholar
• Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med 2007;24(9):955-61
   PubMed Web of Science ®Google Scholar
• Goke B, Hershon K, Kerr D, Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008;40(12):892-5
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Dejager S, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30(2):217-23
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Niggli M, Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009
   Web of Science ®Google Scholar
• Pan C, Yang W, Barona JP, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008;25(4):435-41
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Schweizer A, Mari A, Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(8):675-82
   PubMed Web of Science ®Google Scholar
• Scherbaum WA, Schweizer A, Mari A, Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008;10(11):1114-24
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76(1):132-8
   PubMed Web of Science ®Google Scholar
• Pratley RE, Rosenstock J, Pi-Sunyer FX, Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 2007;30(12):3017-22
   PubMed Web of Science ®Google Scholar
• Ahren B, Gomis R, Standl E, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27(12):2874-80
   PubMed Web of Science ®Google Scholar
• Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009;11(5):506-15
   PubMed Web of Science ®Google Scholar
• Garber AJ, Foley JE, Banerji MA, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008;10(11):1047-56
   PubMed Web of Science ®Google Scholar
• Serra D, He YL, Bullock J, Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with type 2 diabetes. Int J Clin Pharmacol Ther 2008;46(7):349-64
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes Metab 2008;10(1):82-90
   PubMed Web of Science ®Google Scholar
• Bolli G, Dotta F, Colin L, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009;11(6):589-95
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Fonseca V, Zinman B, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11(2):157-66
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9(2):166-74
   PubMed Web of Science ®Google Scholar
• Bosi E, Camisasca RP, Collober C, Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-5
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Kim SW, Baron MA, Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9(2):175-85
   PubMed Web of Science ®Google Scholar
• Fonseca V, Schweizer A, Albrecht D, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007;50(6):1148-55
   PubMed Web of Science ®Google Scholar
• Fonseca V, Baron M, Shao Q, Dejager S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Horm Metab Res 2008;40(6):427-30
   PubMed Web of Science ®Google Scholar
• Boschmann M, Engeli S, Dobberstein K, Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009;94(3):846-52
   PubMed Web of Science ®Google Scholar
• Matikainen N, Manttari S, Schweizer A, Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49(9):2049-57
   PubMed Web of Science ®Google Scholar
• Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008;(2):CD006739
   PubMed Web of Science ®Google Scholar
• Montori VM. Vildagliptin was noninferior to rosiglitazone for glycemic control in type 2 diabetes but caused less weight gain. ACP J Club 2007;146(3):74
   PubMedGoogle Scholar
• Rosenstock J, Baron MA, Dejager S, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30(2):217-23
   PubMed Web of Science ®Google Scholar
• He YL, Ligueros-Saylan M, Sunkara G, Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol 2008;48(1):85-95
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Dole K, He YL, Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Curr Med Res Opin 2007;23(12):2913-20
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Sunkara G, Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers. J Clin Pharmacol 2007;47(8):998-1004
   PubMed Web of Science ®Google Scholar
• He YL, Sabo R, Riviere GJ, Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin 2007;23(5):1131-8
   PubMed Web of Science ®Google Scholar
• Hildebrandt M, Reutter W, Arck P, A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci 2000;99(2):93-104
   Web of Science ®Google Scholar